Simultaneous Measurement and Responsive Treatment (SMART01): A Feasibility Study of the SynerG TM CGM sensor Integrated with the Niia Essential Insulin Patch Pump System in Persons with Type 1 Diabetes.

Start Date24 Mar 2025

Sponsor / Collaborator-

ACTRN12625000054415

/ Not yet recruitingNot ApplicableIIT

Effect of early automated insulin delivery on HbA1c and equity in young Maori and/or Pacific Peoples with type 1 diabetes (Early AID Study)

Start Date27 Jan 2025

Sponsor / Collaborator-

IRCT20241103063580N1

/ RecruitingNot ApplicableIIT

Effect of Coughing Technique, ShotBlocker, and Vibration on Pain and Satisfaction During Subcutaneous Insulin Injections for Adults Patients with Type 2 Diabetes mellitus: A Randomized Controlled Trial

Start Date01 Dec 2024

Sponsor / Collaborator-

100 Clinical Results associated with NNC0268-0965

100 Translational Medicine associated with NNC0268-0965

100 Patents (Medical) associated with NNC0268-0965

121,604

Literatures (Medical) associated with NNC0268-0965

31 Dec 2025·ANNALS OF MEDICINE

Bioengineering and omics approaches for Type 1 diabetes practical research: advancements and constraints

Review

Author: Li, Ling ; An, Zhenmei ; Peng, Yihua ; Peng, Xi ; Zhou, Guangju

Insulin dependency arises from autoimmunity that targets the β cells of the pancreas, resulting in Type 1 diabetes (T1D). Despite the fact that T1D patients require insulin for survival, insulin does not provide a cure for this disease or prevent its complications. Despite extensive genetic, molecular, and cellular research on T1D over the years, the translation of this understanding into effective clinical therapies continues to pose a significant obstacle. It is therefore difficult to develop effective clinical treatment strategies without a thorough understanding of disease pathophysiology. Pancreatic tissue bioengineering models of human T1D offer a valuable approach to examining and controlling islet function while tackling various facets of the condition. And in recent years, due to advances in high-throughput omics analysis, the genotypic and molecular profiles of T1D have become finer tuned. The present article will examine recent progress in these areas, along with their utilization and constraints in the realm of T1D.

31 Dec 2025·Journal of Pharmaceutical Policy and Practice

Emergency medicine pharmacists’ interventions in the tertiary hospitals’ emergency departments in Malaysia

Article

Author: Teh, Lih Jiuan ; Tan, Shirlyn ; Tan, Sherene Su Ann ; Bhuvanendran Pillai, Anaanthan ; Selvaratanam, Manimegahlai ; Sia, Rosalind Guen Lin ; Guee, Xin Nee ; Koh, Hock Peng ; Koo, Yee Ping ; Wong, Wai Kit ; Chen, Mary Siew Yng ; Ab Jalal, Haliza

Background:

The emergency medicine (EM) pharmacist is an integrated part of the Emergency Department (ED) interdisciplinary team in many countries, including Malaysia. The presence of EM pharmacists in the ED has positively impacted patient outcomes. Data on EM pharmacists' interventions is scarce in the Asian region. In Malaysia, data on interventions done by EM pharmacists in the EDs was unavailable. This study aimed to assess the type of interventions done by EM pharmacists in the ED of tertiary public hospitals in Malaysia.

Methods:

This cross-sectional, multicenter study involved EM pharmacists from 14 tertiary hospitals in Malaysia. All accepted interventions done by EM pharmacists in the ED for patients admitted to the Red (critical) and Yellow (semi-critical) zones from January to June 2022 were extracted from the Clinical Pharmacy Report Form. All data were analyzed descriptively.

Results:

The EM pharmacists documented 1659 accepted interventions on 1584 patients during the study period. Inappropriate regimens (n = 1117, 67.3%) and incomplete prescriptions (n = 339, 20.4%) were the main categories of accepted interventions in ED. Inappropriate drug (n = 574, 34.6%), dose (n = 292, 17.6%), and frequency (n = 176, 10.6%) were the top three subcategory interventions documented under inappropriate regimens. Antimicrobials, antihypertensives, and proton pump inhibitors were the commonest drug intervened under the categories of inappropriate drug intervention. There were 272 (16.4%) accepted interventions on high-alert medications (HAMs). Insulin, enoxaparin, and noradrenaline were the most intervened HAMs.

Conclusion:

Inappropriate treatment regimens were the most common intervention category done by EM pharmacists in Malaysia. The significant number of interventions done by EM pharmacists demonstrated the importance of EM pharmacists as integral members of the EM team. This data can help improve the quality of clinical pharmacy services in the ED and is important for the future expansion of clinical pharmacy services in all EDs across Malaysia, neighbouring countries, and other developing countries.

31 Dec 2025·Journal of Pharmaceutical Policy and Practice

Effect of statins and antihyperglycemics on chronic kidney disease in patients with type 2 diabetes mellitus: a retrospective cohort study with a 12-year follow-up

Article

Author: El-Dahiyat, Faris ; Mohammed, Khuloud Jamal ; Al Jaberi, Asma Khaled ; Al Jawamis, Dina Farhan ; Shahwan, Moyad ; Jairoun, Ammar Abdulrahman ; Ping, Chong Chee ; Dawoud, Tasnim ; Ibrahim, Baharudin

Background:

Chronic Kidney Disease (CKD) represents a significant worldwide health challenge, with far-reaching implications for both patients and healthcare systems. This study aimed to identify the incidence of CKD at stages 3-5, analyzed the impact of statin and other antihyperglycemic interventions, on the CKD progression in individuals with T2DM.

Methods:

This was a single-center retrospective cohort study based on data derived from electronic medical records (EMR) of UAE populations with diabetes mellitus, registered at outpatient clinics at Tawam Hospital in Al Ain, UAE, between January 2011 and December 2021. T2DM patients aged ≥ 18 years who had serum HbA1c level ≥ 6.5% and using one of the statin therapies were inclusion criteria. Patients with T1DM, who had undergone permanent renal replacement therapy, with under 1 year of follow-up and missing or incomplete data were excluded from the study. The collected data encompassed socio-demographics, detailed medical history, anthropometric measurements, laboratory analyses, clinical parameters, disease characteristics, and medications.

Results:

Our study included a cohort of 1,003 individuals. We observed 388 subjects developed CKD stages 3-5 across an average monitoring duration of 11.7 years. This resulted in a cumulative incidence of 38.7%, translating to an incidence rate of 38 cases per 1000 person-years. There was a statistically significant difference in the cumulative incidence of CKD stages 3 ± 5 according to statin therapy (P = 0.047). High intensity statin users are more likely to develop a CKD stage 3-5 compared to low/moderate intensity users and to no statin users respectively (44.3% vs 37.9%), (44.3% vs 30.9%). Conversely, the use of Biguanides was associated with a decreased probability of CKD progression (37.9% vs. 52.8%; P = 0.001), whereas Insulin users demonstrated a heightened risk (54.2% vs. 34.1%; P < 0.001).

Conclusion:

The findings emphasise the pivotal role of personalised treatment strategies, particularly concerning statin therapy and other medications, in populations at high risk.

707

News (Medical) associated with NNC0268-0965

23 Apr 2025

·www.prnewswire.com

Breakthrough T1D Awards $2.8 Million in Funding to Expand Center of Excellence at University of Michigan and Oregon Health & Science University to Accelerate Type 1 Diabetes Research

The Breakthrough T1D U-M-OHSU Cardiorenal Center of Excellence to focus on heart and kidney disease in type 1 diabetes NEW YORK, April 23, 2025 /PRNewswire/ -- Breakthrough T1D, formerly JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, has awarded more than $2.8 million over three years for the Breakthrough T1D Center of Excellence at the University of Michigan and Oregon Health & Science University, creating the Breakthrough T1D U-M-OHSU Cardiorenal Center of Excellence. This funding will expand the existing University of Michigan Center of Excellence to include Oregon Health & Science University and create a joint Center of Excellence that will build on the work completed over the last five years at U-M. It will be led by Matthias Kretzler, M.D., with the University of Michigan, and Rodica Pop-Busui, M.D., Ph.D., with Oregon Health & Science University. The Breakthrough T1D Center of Excellence at the University of Michigan has conducted research across focus areas, including beta cell replacement therapies, automated insulin delivery systems, psychosocial health, metabolic control, and long-term complications of the eye, heart, and kidney from T1D. Building on the advances in our understanding of heart and kidney complications in T1D, the new joint Center of Excellence will address a critical research gap by establishing an innovative and efficient clinical trial platform that will be used to test several heart and kidney therapies in people living with T1D. It will also advance work started by the University of Michigan Center of Excellence in precision medicine with the ultimate goal of treating the right person with the right therapy at the right time. "The Breakthrough T1D Center of Excellence at the University of Michigan has advanced our understanding of heart and kidney disease in type 1 diabetes," said Breakthrough T1D Research Director Jonathan Rosen, Ph.D. "The stage is now set for the Breakthrough T1D U-M-OHSU Cardiorenal Center of Excellence to apply these learnings in an innovative clinical trial testing promising heart and kidney therapies in people with T1D. Such trials are urgently needed because there are few therapeutic options available today." "This Breakthrough T1D Center of Excellence represents a bold step forward in our commitment to advancing cutting-edge research for people with type 1 diabetes, and thus expediting true personalized care for patients," Dr. Pop-Busui said. "With this new partnership, we are creating a collaborative hub where scientific discovery and clinical innovation come together to reverse cardiorenal disease in people with type 1 diabetes. Together, we can help transform the future of health." The Harold Schnitzer Diabetes Health Center at OHSU was established in 2007 and endowed by the Harold & Arlene Schnitzer CARE Foundation to advance knowledge and care for people with diabetes. It is the only diabetes center in the Pacific Northwest that provides specialized and outstanding clinical care for children and adults living with T1D in one location. It has state-of-the-art infrastructure and a track record of direct integration of clinical research at the point of care in one location, which will enable a rapid launch of the new Center of Excellence activities and clinical trials. "We are profoundly honored to receive this significant investment from Breakthrough T1D to establish the U-M-OHSU Center of Excellence," said Dr. Kretzler at the University of Michigan. "This award is a testament to the significant contributions we have made in understanding the molecular mechanisms leading to cardiovascular and kidney complications in type 1 diabetes. Our collaboration with Oregon Health & Science University will accelerate the translation of these scientific insights into tangible therapies that can improve the lives of those living with T1D. Together, we will pave the way for expanding treatment options through innovations in clinical trials, leading to the implementation of precision medicine for T1D, ensuring that every person receives the optimal treatment for their condition at the right time." Breakthrough T1D Centers of Excellence align with the organization's research strategy and seek to leverage world-class institutions and researchers' expertise, specialty, and resources to accelerate T1D treatments and therapies. Bringing together leading experts from diverse fields and multiple institutions, each Breakthrough T1D Center of Excellence builds on established expertise to accelerate T1D advances. The Center of Excellence model is designed to maximize resources, remove barriers, link research efforts worldwide, develop the next generation of scientific leadership, and foster maximum collaboration to drive progress as quickly as possible. The Breakthrough T1D U-M-OHSU Cardiorenal Center of Excellence is one of five Breakthrough T1D Centers of Excellence around the world, powering advances to deliver cures and life-improving breakthroughs for T1D. About Breakthrough T1D, Formerly JDRF As the leading global type 1 diabetes research and advocacy organization, Breakthrough T1D helps make everyday life with type 1 diabetes better while driving toward cures. We do this by investing in the most promising research, advocating for progress by working with government to address issues that impact the T1D community, and helping educate and empower individuals facing this condition. About Type 1 Diabetes (T1D) T1D is an autoimmune condition that causes the pancreas to make very little insulin or none at all. This leads to dependence on insulin therapy and the risk of short and long-term complications, which can include highs and lows in blood sugar; damage to the kidneys, eyes, nerves, and heart; and even death. Globally, it impacts nearly 9 million people. Many believe T1D is only diagnosed in childhood and adolescence, but diagnosis in adulthood is common and accounts for nearly 50% of all T1D diagnoses. The onset of T1D has nothing to do with diet or lifestyle. While its causes are not yet entirely understood, scientists believe that both genetic factors and environmental triggers are involved. There is currently no cure for T1D. Contact: Casey Fielder 509-651-0087 [email protected] SOURCE Breakthrough T1D, Formerly JDRF WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Clinical Study

22 Apr 2025

·www.fiercebiotech.com

Biolinq raises $100M to carry glucose sensor patch across the finish line

Biolinq\'s system also features a color-changing indicator light to provide real-time feedback on glucose levels. \n Biolinq has raised $100 million in venture capital financing to help complete the development of its wearable glucose biosensor—proceeds the company said would help set up its commercial efforts while it prepares submissions for U.S. regulatory approval.The coin-sized device, worn on the forearm, can also track sleep and activity data to help provide additional context around the user’s metabolic health. It employs an array of electrochemical sensors capable of measuring multiple analytes under the skin, such as lactate and ketones, without requiring introducer needles or tapping into subcutaneous tissue.The system also features a color-changing indicator light to provide real-time feedback on blood sugar levels.“Biolinq is unlocking a new era of biosensing technology, making glucose information simpler and more accessible,” the company’s chairman, Dan Bradbury, said in a statement. “This technology has the potential to help restore metabolic health for millions of people living with Type 2 diabetes not using insulin.” The company’s series C financing round was led by Alpha Wave Ventures and counted previous backers among RiverVest Venture Partners, AXA IM Alts, LifeSci Venture Partners, M Ventures, Hikma Ventures, Aphelion Capital, Taisho Pharmaceutical and Features Capital.About one year ago, in April 2024, Biolinq raised $58 million to be put toward the completion of a pivotal clinical trial. That fundraising was also led by Alpha Wave Ventures. “Biolinq has attracted leading experts in biosensor development, consumer electronics design, proprietary materials science, software engineering and semiconductor manufacturing to build a new category of biowearables,” Rick Gerson, chairman of Alpha Wave Global, said at the time. Prior to that, the company raised $100 million through a series B round in late 2021.

AHA

22 Apr 2025

·www.mobihealthnews.com

Biolinq raises $100M for intradermal glucose sensor for type 2 diabetes

Biolinq, a health technology company developing precision multi-analyte wearable biosensors for metabolic health, announced it secured $100 million in Series C funding. Alpha Wave Ventures led the round with participation from existing investors AXA IM Alts, M Ventures, LifeSci Venture Partners, RiverVest Venture Partners, Hikma Ventures, Taisho Pharmaceutical, Features Capital and Aphelion Capital. WHAT IT DOES Biolinq offers a wearable patch that evaluates glucose levels and provides insights into metabolic health for individuals with type 2 diabetes who are not on insulin. The patch uses small electrochemical sensors to measure glucose levels from the intradermal space just beneath the skin's surface. The California-based company's glucose sensor is an investigational device that has not been cleared or approved by the FDA. "This financing will bolster Biolinq's commercial readiness efforts while we pursue regulatory approval for the first intradermal glucose sensor that incorporates activity and sleep information into a single wearable device," Rich Yang, CEO of Biolinq, said in a statement. "Our team has spent the last decade developing a biosensor platform designed to inspire healthier living by providing context around a person's metabolic health." MARKET SNAPSHOT Last year, Biolinq secured $58 million in financing, which the company said it would use for FDA submission and to perform a clinical trial on its glucose sensor. The company raised $4.75 million in extended Series A financing in 2019 and secured $20 million in Series A funding in 2017. Another company in the glucose monitoring space is Allez Health, which offers a CGM biosensor platform that uses sensor technology to improve a patient's performance by analyzing datasets across various health afflictions. Last year, the company secured $60 million in Series A+ financing.

100 Deals associated with NNC0268-0965

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	Phase 1	Germany	Novo Nordisk A/S	29 Oct 2019
Diabetes Mellitus, Type 1	Phase 1	Germany	Novo Nordisk A/S	05 Jun 2019

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


WSC2023	Not Applicable	Sleep Apnea Syndromes	-	Diabetic Patients on Insulin Therapy	iyprykwjym(pmbxzgwkyl) = jzmjgayetk qodektwjxk (jpbzfugpbo, 0.02) View more	-	23 Oct 2023
STOP study (EASD2023)	Not Applicable	Diabetes Mellitus, Type 2	93	IDegLira	sxucyhxojx(drqcqudqkb) = cfacjioyya gbhnoywgmo (qjjkjbezgl ) View more	Positive	05 Oct 2023
EASD2023	Not Applicable	-	-	Open-source automated insulin delivery (osAID) system	oxvrekgrco(gkcppwbrdr) = rblekwpwlf uatybazbxf (nbsratgqcx ) View more	Positive	05 Oct 2023
				insulin (Medtronic 780G with SmartGuard)	oxvrekgrco(gkcppwbrdr) = pwaoqfskdd uatybazbxf (nbsratgqcx ) View more
EASD2023	Not Applicable	Diabetes Mellitus, Type 1 \| Diabetic Retinopathy \| Retinal Diseases	652	automated insulin delivery systems (Multiple Daily Injections (MDI))	zysqmaixig(onmrnenclr) = Significantly lower rates of dyslipidemia in patients with AID were seen gxaupxxvkt (nkyxzxurrq ) View more	Positive	05 Oct 2023
				automated insulin delivery systems (Insulin Pump (IP) without AID)
EASD2023	Not Applicable	Diabetes Mellitus, Type 2	514	insulin (Descending mode)	yujhoqwpnx(qunpgcxpje) = zceyssowpv iqkgdlnbpj (thcvxfqcxa, (1.0 - 6.0)) View more	Positive	05 Oct 2023
				insulin (Ascending mode)	yujhoqwpnx(qunpgcxpje) = voindvrcqb iqkgdlnbpj (thcvxfqcxa, (0 - 4.0)) View more
INSENODIAB (ESPE2023)	Not Applicable	Diabetes Mellitus, Type 1	-	Insulin	jwffpdxxcx(cfguxjuqsj) = nlbfqksnfi aclacwcfsc (dsitfwiphb, 0.5)	-	21 Sep 2023
				rINSENODIAB cohort	jwffpdxxcx(cfguxjuqsj) = qiftyhknrd aclacwcfsc (dsitfwiphb, 6.9)
ESPE2023	Not Applicable	Familial chylomicronaemia syndrome LPL deficiency	4	Insulin	gictdjarjy(rbbezrggyb) = jjgzkrwksv eyolhkytrx (iwllylgjvx )	-	21 Sep 2023
ADA2023	Not Applicable	Diabetes Mellitus, Type 2	96	Basal insulin only	akppnrqakg(hjamsxauqi) = okixzwmfuj sekivmzjma (aatoazfvxr ) View more	-	23 Jun 2023
				Multiple daily injections (MDI)	akppnrqakg(hjamsxauqi) = iqzmwzxmey sekivmzjma (aatoazfvxr ) View more
ADA2023	Not Applicable	Pregnancy	-	Concentrated insulin in continuous subcutaneous insulin infusion (CSII)	dkxhonvdvv(uixtttsmde) = vcvhlvhgvc befabjxopn (sfpjteshqt ) View more	-	20 Jun 2023
ADA2023	Not Applicable	-	-	Insulin + Glucagon	rfmwsnvnqn(lglrpjaqeb) = victudxbxk qpevyfmomw (xuhklwaozm )	-	20 Jun 2023
				Insulin	rfmwsnvnqn(lglrpjaqeb) = swfmjndesc qpevyfmomw (xuhklwaozm )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

NNC0268-0965

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation